Home Newsfeeds Lifecore Biomedical Signs Term Sheet With Existing Long-Term Customer To Expand CDMO Relationship

Lifecore Biomedical Signs Term Sheet With Existing Long-Term Customer To Expand CDMO Relationship

Provides $10 million upfront cash commitment to Lifecore for infrastructure preparation and production capacity preparation

byBenzinga Newsdesk

March 16, 2023

1 minute read

Provides $10 million upfront cash commitment to Lifecore for infrastructure preparation and production capacity preparation

Lululemon Athletica Expects Q4 Net Revenue of $3.170B-$3.190B (Prior $3.135B-$3.170B), EPS of $4.96-$5.00 (Prior $4.85-$4.93), Gross Margin of 58.6%-58.7% (Prior 58.3%-58.6%)

By Benzinga Newsdesk

January 8, 7:36 AM

lululemon athletica inc. (NASDAQ:LULU) today announced that, for the fourth quarter of fiscal 2023, the Company now expects net revenue will be in the range of $3.170 billion to $3.190 billion,

LULU

US Stocks Mixed; Dow Gains 50 Points

By Lisa Levin

June 16, 9:49 AM

U.S. stocks traded mixed this morning, with Dow Jones gaining around 50 points on Friday. Following the market opening Friday, the Dow traded up 0.16% to 34,464.01 while the NASDAQ fell 0.14% to 13,763.40. The S&P 500, also rose, gaining, 0.10% to 4,430.43.

ADBE

Macquarie Maintains Underperform on Netflix, Raises Price Target to $170

By Benzinga Newsdesk

July 20, 7:07 AM

Macquarie analyst Tim Nollen maintains Netflix (NASDAQ:NFLX) with a Underperform and raises the price target from $150 to $170.

NFLX

Sarepta Says Statistically Significant Results On All Key Pre-specified Secondary Endpoints Demonstrated Evidence Of Clinically Meaningful Treatment Benefit

By Benzinga Newsdesk

October 30, 4:05 PM

– Results support submission of an efficacy supplement to the BLA; US FDA has indicated openness to reviewing the data for label expansion based on the totality of evidence from EMBARK– In EMBARK, participants

SRPT

Lifecore Biomedical Signs Term Sheet With Existing Long-Term Customer To Expand CDMO Relationship

Related Posts

Lululemon Athletica Expects Q4 Net Revenue of $3.170B-$3.190B (Prior $3.135B-$3.170B), EPS of $4.96-$5.00 (Prior $4.85-$4.93), Gross Margin of 58.6%-58.7% (Prior 58.3%-58.6%)

US Stocks Mixed; Dow Gains 50 Points

Macquarie Maintains Underperform on Netflix, Raises Price Target to $170

Sarepta Says Statistically Significant Results On All Key Pre-specified Secondary Endpoints Demonstrated Evidence Of Clinically Meaningful Treatment Benefit